Scarica l'app Stockscreener
8.13
2.14%
0.17
Dopo l'orario di chiusura:
8.13
Precedente Chiudi:
$7.96
Aprire:
$8.29
Volume 24 ore:
2.61M
Relative Volume:
1.55
Capitalizzazione di mercato:
$2.55B
Reddito:
$2.68B
Utile/perdita netta:
$-184.45M
Rapporto P/E:
-11.95
EPS:
-0.6805
Flusso di cassa netto:
$229.23M
1 W Prestazione:
+0.49%
1M Prestazione:
-3.44%
6M Prestazione:
+1.88%
1 anno Prestazione:
+21.34%
Intervallo 1D:
$8.03
$8.565
Intervallo di 1 settimana:
$7.665
$8.565
Portata 52W:
$6.59
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Nome
Amneal Pharmaceuticals Inc
Settore
Telefono
908-947-3120
Indirizzo
400 Crossing Boulevard, 3rd Floor, Bridgewater
Confronta AMRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
8.13 | 2.45B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
146.12 | 65.61B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.20 | 44.72B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.29 | 43.39B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.71 | 17.64B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
304.81 | 13.31B | 2.99B | 1.21B | 1.13B | 25.06 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-06 | Iniziato | Goldman | Buy |
| 2025-02-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Aggiornamento | Goldman | Sell → Buy |
| 2020-12-14 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-27 | Iniziato | Goldman | Sell |
| 2020-05-12 | Aggiornamento | Guggenheim | Sell → Neutral |
| 2019-12-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-21 | Aggiornamento | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-03-08 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Downgrade | SunTrust | Buy → Hold |
| 2018-08-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Iniziato | Morgan Stanley | Overweight |
| 2018-06-22 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie
Amneal Pharmaceuticals' 2025Q2 Earnings Call: Key Contradictions on RYTARY, CREXONT, and Margin Strategies - AInvest
Amneal Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Amneal Pharma Q2 2025 EPS beats forecast By Investing.com - Investing.com Canada
Amneal Pharmaceuticals Stock Rises Amid Growth Signals - TipRanks
Amneal Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Amneal (AMRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Amneal Raises Outlook Even As Revenue Falls Short - Finimize
Amneal Pharmaceuticals Lifts Annual Earnings Outlook As Q2 Net Income Surges; Pre-Market Stock Up - Nasdaq
Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates - Yahoo Finance
Amneal Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Amneal Pharma A earnings beat by $0.08, revenue fell short of estimates - Investing.com Canada
Amneal: Q2 Earnings Snapshot - San Francisco Chronicle
Amneal Pharmaceuticals beats Q2 estimates, raises full-year outlook - Investing.com
Amneal (NASDAQ:AMRX) Misses Q2 Sales Targets - TradingView
Amneal Pharmaceuticals Reports Strong Q2 2025 Results and Raises Full Year Guidance Following Successful Debt Refinancing - Quiver Quantitative
Amneal Reports Second Quarter 2025 Financial Results - GlobeNewswire
Amneal Pharmaceuticals Set to Announce Earnings Amid Market ChallengesNews and Statistics - IndexBox
Amneal Earnings: What To Look For From AMRX - Yahoo Finance
How does Amneal Pharmaceuticals Inc. compare to its industry peersRapid growth opportunities - Jammu Links News
How many analysts rate Amneal Pharmaceuticals Inc. as a “Buy”Consistent triple returns - Jammu Links News
What is Amneal Pharmaceuticals Inc. company’s growth strategyAccelerated profit realization - Jammu Links News
Is Amneal Pharmaceuticals Inc. a good long term investmentFree Wealth Management Insights - Jammu Links News
What analysts say about Amneal Pharmaceuticals Inc. stockStay informed with daily expert analysis - Jammu Links News
How strong is Amneal Pharmaceuticals Inc. company’s balance sheetExceptional profit velocity - Jammu Links News
What makes Amneal Pharmaceuticals Inc. stock price move sharplyTransform your portfolio with high-yield stocks - Jammu Links News
What are the technical indicators suggesting about Amneal Pharmaceuticals Inc.Free Investment Community - Jammu Links News
Is Amneal Pharmaceuticals Inc. a growth stock or a value stockTremendous growth opportunities - Jammu Links News
What are Amneal Pharmaceuticals Inc. company’s key revenue driversExponentially increasing returns - Jammu Links News
What is the dividend policy of Amneal Pharmaceuticals Inc. stockUnlock your portfolio’s full growth potential - Jammu Links News
Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space - MSN
What drives Amneal Pharmaceuticals Inc. stock priceDiscover high-impact stocks for growth - Jammu Links News
Amneal Pharmaceuticals Secures $2.1 Billion in Loans to Refinance Debts and Enhance Financial Flexibility - AInvest
Truist Financial Keeps Buy Rating on Amneal Pharmaceuticals with $8 PT - AInvest
Amneal Pharmaceuticals Secures $2.1 Billion in Loans - TipRanks
Amneal Pharmaceuticals Inc expected to post earnings of 18 cents a shareEarnings Preview - TradingView
Truist Financial Maintains a Buy on Amneal Pharmaceuticals (AMRX) With an $8 PT - MSN
Amneal Launches GLP-1 Agonist Exenatide Injection - Specialty Pharmacy Continuum
Teva Drops Inhaler Patent Infringement Lawsuit Against Amneal - Bloomberg Law News
Is Amneal Pharmaceuticals Inc. a candidate for recovery playReversal Alert Based on RSI Indicator Confirmed - metal.it
Amneal Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayStock Market Watch With Alerts Shows Unusual Activity - metal.it
Teva, Amneal End Case Over Listing Inhaler IP In Orange Book - Law360
Why Amneal Pharmaceuticals Inc. stock attracts strong analyst attentionAI Driven Stock Trend Forecast Shows Momentum Shift - metal.it
Amneal (AMRX) is an Incredible Growth Stock: 3 Reasons Why - sharewise.com
Wall Street Analysts Think Amneal (AMRX) Could Surge 43.82%: Read This Before Placing a Bet - Zacks Investment Research
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Q1 Earnings Highlights: Amneal, ANI, Amphastar, and ViatrisNews and Statistics - IndexBox
Q1 Earnings Highs And Lows: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks - Yahoo Finance
Published on: 2025-07-29 09:45:24 - metal.it
Published on: 2025-07-28 20:38:28 - metal.it
Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
What institutional investors are buying Amneal Pharmaceuticals Inc. stockExceptional earning trajectories - Jammu Links News
Amneal Pharmaceuticals Inc Azioni (AMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.64%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):